MA34545B1 - Co-cristaux et sels d'inhibiteurs de ccr3 - Google Patents
Co-cristaux et sels d'inhibiteurs de ccr3Info
- Publication number
- MA34545B1 MA34545B1 MA35770A MA35770A MA34545B1 MA 34545 B1 MA34545 B1 MA 34545B1 MA 35770 A MA35770 A MA 35770A MA 35770 A MA35770 A MA 35770A MA 34545 B1 MA34545 B1 MA 34545B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystals
- salts
- ccr3 inhibitors
- ccr3
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Cette invention concerne des co-cristaux et des sels d'inhibiteurs de CCR3 de formule (1), des compositions pharmaceutiques les contenant et des procédés d'utilisation de ceux-ci en tant qu'agents pour le traitement et/ou la prévention de maladies associées au récepteur CCR3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10186901 | 2010-10-07 | ||
PCT/EP2011/067437 WO2012045803A1 (fr) | 2010-10-07 | 2011-10-06 | Co-cristaux et sels d'inhibiteurs de ccr3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34545B1 true MA34545B1 (fr) | 2013-09-02 |
Family
ID=44741339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35770A MA34545B1 (fr) | 2010-10-07 | 2011-10-06 | Co-cristaux et sels d'inhibiteurs de ccr3 |
Country Status (36)
Country | Link |
---|---|
US (3) | US8742115B2 (fr) |
EP (1) | EP2625174B1 (fr) |
JP (1) | JP5794713B2 (fr) |
KR (3) | KR101844215B1 (fr) |
CN (1) | CN103140486B (fr) |
AP (1) | AP3268A (fr) |
AR (1) | AR083353A1 (fr) |
AU (1) | AU2011311530B2 (fr) |
BR (2) | BR122021010665B1 (fr) |
CA (1) | CA2807255C (fr) |
CL (1) | CL2013000488A1 (fr) |
CO (1) | CO6710910A2 (fr) |
CY (1) | CY1116168T1 (fr) |
DK (1) | DK2625174T3 (fr) |
EA (1) | EA029097B1 (fr) |
EC (1) | ECSP13012600A (fr) |
ES (1) | ES2535264T3 (fr) |
GE (1) | GEP20166488B (fr) |
HR (1) | HRP20150419T1 (fr) |
HU (1) | HUE024540T2 (fr) |
IL (1) | IL224269A (fr) |
MA (1) | MA34545B1 (fr) |
ME (1) | ME02040B (fr) |
MX (1) | MX2013003785A (fr) |
MY (1) | MY167898A (fr) |
NZ (1) | NZ605827A (fr) |
PE (1) | PE20140188A1 (fr) |
PL (1) | PL2625174T3 (fr) |
PT (1) | PT2625174E (fr) |
RS (1) | RS53858B1 (fr) |
SG (1) | SG188949A1 (fr) |
SI (1) | SI2625174T1 (fr) |
TW (1) | TWI546294B (fr) |
UA (1) | UA109290C2 (fr) |
UY (1) | UY33655A (fr) |
WO (1) | WO2012045803A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US8680280B2 (en) * | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
AU2018248425B2 (en) | 2017-04-05 | 2024-03-28 | Alkahest Inc. | Methods and compositions for treating retina-associated disease using CCR3-inhibitors |
US20200054622A1 (en) * | 2017-04-05 | 2020-02-20 | Alkahest, Inc. | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors |
BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
JP2020536929A (ja) * | 2017-10-13 | 2020-12-17 | アルカヘスト,インコーポレイテッド | Ccr3阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物 |
WO2019222265A1 (fr) | 2018-05-15 | 2019-11-21 | Alkahest, Inc. | Traitement d'une maladie associée au vieillissement avec des modulateurs de la leucotriène a4 hydrolase |
BR112021004938A2 (pt) * | 2018-09-26 | 2021-06-01 | Alkahest, Inc. | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 |
AU2021287906A1 (en) * | 2020-06-11 | 2022-12-15 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7907121L (sv) | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
US6433165B1 (en) | 1998-01-21 | 2002-08-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
EP1052992A1 (fr) | 1998-02-02 | 2000-11-22 | Merck & Co., Inc. | Amines cycliques utilisees en tant que modulateurs de l'activite du recepteur de chemokine |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
US6936718B2 (en) | 2001-11-29 | 2005-08-30 | Schering Corporation | Preparation of rotamer mixtures of pharmaceutical salts |
EP1596869B1 (fr) * | 2003-01-21 | 2014-06-04 | New Form Pharmaceuticals Inc. | Nouvelle co-cristallisation |
KR20060061393A (ko) | 2003-10-24 | 2006-06-07 | 에프. 호프만-라 로슈 아게 | Ccr3 수용체 길항제 |
US7705153B2 (en) | 2004-02-05 | 2010-04-27 | Schering Corporation | Bipiperdine derivatives useful as CCR3 antagonists |
US7803786B2 (en) | 2004-06-17 | 2010-09-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
JP2006137718A (ja) | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
WO2007116313A2 (fr) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Composés chimiques |
DE602007008222D1 (de) | 2006-04-20 | 2010-09-16 | Hoffmann La Roche | Diazepanderivate als modulatoren von chemokinrezeptoren |
GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2011
- 2011-06-10 UA UAA201305572A patent/UA109290C2/ru unknown
- 2011-10-06 TW TW100136338A patent/TWI546294B/zh active
- 2011-10-06 AR ARP110103717A patent/AR083353A1/es unknown
- 2011-10-06 US US13/267,417 patent/US8742115B2/en active Active
- 2011-10-06 JP JP2013532190A patent/JP5794713B2/ja active Active
- 2011-10-06 ME MEP-2015-17A patent/ME02040B/me unknown
- 2011-10-06 DK DK11764572.1T patent/DK2625174T3/da active
- 2011-10-06 SG SG2013013305A patent/SG188949A1/en unknown
- 2011-10-06 CN CN201180047995.1A patent/CN103140486B/zh active Active
- 2011-10-06 KR KR1020137008683A patent/KR101844215B1/ko active IP Right Grant
- 2011-10-06 SI SI201130394T patent/SI2625174T1/sl unknown
- 2011-10-06 MX MX2013003785A patent/MX2013003785A/es active IP Right Grant
- 2011-10-06 RS RS20150131A patent/RS53858B1/en unknown
- 2011-10-06 BR BR122021010665-7A patent/BR122021010665B1/pt active IP Right Grant
- 2011-10-06 GE GEAP201113082A patent/GEP20166488B/en unknown
- 2011-10-06 CA CA2807255A patent/CA2807255C/fr active Active
- 2011-10-06 AU AU2011311530A patent/AU2011311530B2/en active Active
- 2011-10-06 MA MA35770A patent/MA34545B1/fr unknown
- 2011-10-06 HU HUE11764572A patent/HUE024540T2/hu unknown
- 2011-10-06 NZ NZ605827A patent/NZ605827A/en unknown
- 2011-10-06 PE PE2013000781A patent/PE20140188A1/es not_active Application Discontinuation
- 2011-10-06 UY UY0001033655A patent/UY33655A/es unknown
- 2011-10-06 PT PT11764572T patent/PT2625174E/pt unknown
- 2011-10-06 ES ES11764572.1T patent/ES2535264T3/es active Active
- 2011-10-06 BR BR112013008211-9A patent/BR112013008211B1/pt active IP Right Grant
- 2011-10-06 WO PCT/EP2011/067437 patent/WO2012045803A1/fr active Application Filing
- 2011-10-06 EA EA201300436A patent/EA029097B1/ru unknown
- 2011-10-06 PL PL11764572T patent/PL2625174T3/pl unknown
- 2011-10-06 KR KR1020197025850A patent/KR102239690B1/ko active IP Right Grant
- 2011-10-06 EP EP11764572.1A patent/EP2625174B1/fr active Active
- 2011-10-06 MY MYPI2013000801A patent/MY167898A/en unknown
- 2011-10-06 KR KR1020177037823A patent/KR102163874B1/ko active IP Right Grant
- 2011-10-06 AP AP2013006679A patent/AP3268A/xx active
-
2013
- 2013-01-17 IL IL224269A patent/IL224269A/en unknown
- 2013-02-19 CL CL2013000488A patent/CL2013000488A1/es unknown
- 2013-04-08 CO CO13090552A patent/CO6710910A2/es unknown
- 2013-05-03 EC ECSP13012600 patent/ECSP13012600A/es unknown
-
2014
- 2014-01-22 US US14/160,646 patent/US20140135307A1/en not_active Abandoned
- 2014-12-17 US US14/572,889 patent/US9233950B2/en active Active
-
2015
- 2015-04-07 CY CY20151100331T patent/CY1116168T1/el unknown
- 2015-04-15 HR HRP20150419TT patent/HRP20150419T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MA47043A1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
EA201390683A1 (ru) | Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp | |
MA40219A (fr) | Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
MA35407B1 (fr) | Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine | |
MA35268B1 (fr) | 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
MA32224B1 (fr) | Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
MA39020A1 (fr) | Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique | |
ATE525370T1 (de) | Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten | |
MA39719B1 (fr) | Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA56098B1 (fr) | Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1 |